This is a working overview of Tuftsin analogue, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-08 and is reviewed periodically as new material appears.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analog of the tetrapeptide tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Reported consistently across pharmacopoeial descriptions |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| Solubility | Freely soluble in water | Aqueous buffers; poor in nonpolar solvents |
| Typical storage temperature | -20 degrees Celsius | Lyophilized powder; protect from moisture |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.
Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.
Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.
=== Secretions === Basophils arise and mature in bone marrow. When activated, basophils degranulate to release histamine, proteoglycans (e.g. heparin and chondroitin), and proteolytic enzymes (e.g. elastase and lysophospholipase). They also secrete lipid mediators like leukotrienes (LTD-4), and several cytokines. Histamine and proteoglycans are pre-stored in the cell's granules while the other secreted substances are newly generated. Each of these substances contributes to inflammation. Recent evidence suggests that basophils are an important source of the cytokine, interleukin-4, perhaps more important than T cells. Interleukin-4 is considered one of the critical cytokines in the development of allergies and the production of IgE antibody by the immune system. There are other substances that can activate basophils to secrete which suggests that these cells have other roles in inflammation. The degranulation of basophils can be investigated in vitro by using flow cytometry and the so-called basophil-activation-test (BAT). Especially, in the diagnosis of allergies including of drug reactions (e.g. induced by contrast medium), the BAT is of great impact. Basopenia (a low basophil count) is difficult to demonstrate as the normal basophil count is so low; it has been reported in association with autoimmune urticaria (a chronic itching condition). Basophilia is also uncommon but may be seen in some forms of leukemia or lymphoma.
[A] is the concentration of reagent A, etc. It is possible in principle to obtain values of the activity coefficients, γ. For solutions, equations such as the Debye–Hückel equation or extensions such as Davies equation Specific ion interaction theory or Pitzer equations may be used. However this is not always possible. It is common practice to assume that Γ is a constant, and to use the concentration quotient in place of the thermodynamic equilibrium constant. It is also general practice to use the term equilibrium constant instead of the more accurate concentration quotient. This practice will be followed here. For reactions in the gas phase partial pressure is used in place of concentration and fugacity coefficient in place of activity coefficient. In the real world, for example, when making ammonia in industry, fugacity coefficients must be taken into account. Fugacity, f, is the product of partial pressure and fugacity coefficient. The chemical potential of a species in the real gas phase is given by
World War II caused a pause in palaeontological research; after the war, research attention was also diverted increasingly to fossil mammals rather than dinosaurs, which were seen as sluggish and cold-blooded. At the end of the 1960s, however, the field of dinosaur research experienced a surge in activity that remains ongoing. Several seminal studies led to this activity. First, John Ostrom discovered the bird-like dromaeosaurid theropod Deinonychus and described it in 1969. Its anatomy indicated that it was an active predator that was likely warm-blooded, in marked contrast to the then-prevailing image of dinosaurs. Concurrently, Robert T. Bakker published a series of studies that likewise argued for active lifestyles in dinosaurs based on anatomical and ecological evidence (see § Physiology), which were subsequently summarized in his 1986 book The Dinosaur Heresies.
=== 1990s === In the early 1990s, Wolverine featured as a prominent character in X-Men vol. 2, initially written by Claremont and illustrated by Jim Lee. The first issue of this series is the highest selling comic book issue in history, selling more than eight million copies. During this period, Wolverine regularly appeared in cover stories for the anthology series Marvel Comics Presents, due to a mandate from Marvel's sales department, which noticed that sales of the series were always higher for issues in which Wolverine was featured. Among these stories was "Weapon X", written and drawn by Windsor-Smith, serialized in issues #72–84 (1991). The story depicts Wolverine's past, how adamantium was grafted to his skeleton, and his experience of extreme psychological and physical trauma. Subsequent Wolverine stories in Marvel Comics Presents were often illustrated by Sam Kieth and had a more psychedelic aesthetic and storytelling style. Wolverine returned to his original blue-and-yellow costume in this period. Wolverine starred in a popular new story arc in X-Men after Claremont's departure, plotted by Byrne and Lee, that revealed more about Wolverine's past and the consequences of the Weapon X program.
Sources: en.wikipedia.org
In common with other nitriles, acetonitrile can be metabolised in microsomes, especially in the liver, to produce hydrogen cyanide, as was first shown by Pozzani et al. in 1959. The first step in this pathway is the oxidation of acetonitrile to glycolonitrile by an NADPH-dependent cytochrome P450 monooxygenase. The glycolonitrile then undergoes a spontaneous decomposition to give hydrogen cyanide and formaldehyde. Formaldehyde, a toxin and a carcinogen on its own, is further oxidized to formic acid, which is another source of toxicity. The metabolism of acetonitrile is much slower than that of other nitriles, which accounts for its relatively low toxicity. Hence, one hour after administration of a potentially lethal dose, the concentration of cyanide in the rat brain was 1/20 that for a propionitrile dose 60 times lower (see table). The relatively slow metabolism of acetonitrile to hydrogen cyanide allows more of the cyanide produced to be detoxified within the body to thiocyanate (the rhodanese pathway). It also allows more acetonitrile to be excreted unchanged before it is metabolised. The main pathways of excretion are by exhalation and in the urine.
=== Post-war expansion of the Rowett Research Institute === When Boyd Orr returned to Aberdeen in early 1919, his plan for a larger Institute had still not been accepted. Indeed, even his plans for the annual maintenance grant had to be approved by the Professor of Agriculture in Cambridge, Thomas Barlow Wood. Despite gaining the latter's support, his expansion plans were at first rebuffed, although he succeeded in having the annual grant increased to £4,000. In 1920 he was introduced to John Quiller Rowett, a businessman who seemed to have qualms of conscience over the large profits he had made during the war. Shortly afterwards, the government agreed to finance half the cost of Boyd Orr's plan, provided he could raise the other half elsewhere. Rowett agreed to provide £10,000 for the first year, £10,000 for the second year, and gave an additional £2,000 for the purchase of a farm, provided that, "if any work done at the Institute on animal nutrition was found to have a bearing on human nutrition, the Institute would be allowed to follow up this work", a condition the Treasury was willing to accept. By September 1922 the buildings were nearly completed, and the renamed Rowett Research Institute was opened shortly thereafter by Queen Mary. Boyd Orr proved to be an effective fund-raiser from both government and private sources, expanding the experimental farm to around 1,000 acres (400 hectares), building a well-endowed library, and expanding the buildings.
Robert Blake, Assistant Secretary of State for South and Central Asian Affairs, dismissed any concerns over a rift with India regarding American Af-Pak policy. Calling India and the United States "natural allies", Blake said that the United States cannot afford to meet the strategic priorities in Pakistan and Afghanistan at "the expense of India". India criticized the Obama administration's decision to limit H-1B (temporary) visas, and India's then External Affairs Minister Pranab Mukherjee (later, the president of India until 2017) said that India would oppose US "protectionism" at various international forums. India's Commerce Minister Kamal Nath said that India may move against Obama's outsourcing policies at the World Trade Organization. In May 2009, Obama reiterated his anti-outsourcing views and criticized the current US tax policy "that says you should pay lower taxes if you create a job in Bangalore, India, than if you create one in Buffalo, New York." However, during the US India Business Council meeting in June 2009, U.S. Secretary of State Hillary Clinton advocated for stronger economic ties between India and the United States. She also rebuked protectionist policies, saying that the U.S will not use the 2008 financial crisis as an excuse to implement protectionism. In June 2010, the United States and India formally re-engaged the US-India Strategic Dialogue initiated under President Bush when a large delegation of high-ranking Indian officials, led by External Affairs Minister S. M. Krishna, visited Washington, D.C.
Sources: en.wikipedia.org
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.
The first four residues of Selank reproduce the tuftsin sequence Thr-Lys-Pro-Arg. A Pro-Gly-Pro extension at the C-terminus was added to slow enzymatic breakdown and extend residence time.
It holds marketing authorization in Russia, where nasal drop formulations are sold. No equivalent approval exists in the European Union, the United States, or most other countries.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.